LT5153B - Chemiškai modifikuoto insulino įvedimas į plaučius - Google Patents

Chemiškai modifikuoto insulino įvedimas į plaučius Download PDF

Info

Publication number: LT5153B
Authority: LT; Lithuania
Prior art keywords: insulin; composition; polyethylene glycol; peg; binding
Prior art date: 2001-05-21

Application number

LT2003107A

Other languages

English (en)

Lithuanian (lt)

Other versions

LT2003107A (en

Inventor

John S. Patton

Mei Chang Kuo

Milton J. Harris

Chester LEACH

Kimberly Perkins

Blaine BUECHE

Original Assignee

Nektar Therapeutics

Nektar Therapeutics Al, Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-21

Filing date

2003-12-17

Publication date

2004-08-25

2003-12-17 Application filed by Nektar Therapeutics, Nektar Therapeutics Al, Corporation filed Critical Nektar Therapeutics

2004-05-25 Publication of LT2003107A publication Critical patent/LT2003107A/xx

2004-08-25 Publication of LT5153B publication Critical patent/LT5153B/lt

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 994
230000002685 pulmonary effect Effects 0.000 title claims description 18
229940125396 insulin Drugs 0.000 claims abstract description 499
102000004877 Insulin Human genes 0.000 claims abstract description 480
108090001061 Insulin Proteins 0.000 claims abstract description 480
210000004072 lung Anatomy 0.000 claims abstract description 79
238000012384 transportation and delivery Methods 0.000 claims abstract description 16
239000000203 mixture Substances 0.000 claims description 237
229920001223 polyethylene glycol Polymers 0.000 claims description 222
239000002202 Polyethylene glycol Substances 0.000 claims description 192
238000000034 method Methods 0.000 claims description 64
210000004369 blood Anatomy 0.000 claims description 49
239000008280 blood Substances 0.000 claims description 49
230000027455 binding Effects 0.000 claims description 46
210000002966 serum Anatomy 0.000 claims description 31
-1 carbonate aldehydes Chemical class 0.000 claims description 25
229920001477 hydrophilic polymer Polymers 0.000 claims description 16
239000000546 pharmaceutical excipient Substances 0.000 claims description 13
125000003277 amino group Chemical group 0.000 claims description 11
239000000178 monomer Substances 0.000 claims description 11
239000000443 aerosol Substances 0.000 claims description 10
150000002148 esters Chemical class 0.000 claims description 9
125000003827 glycol group Chemical group 0.000 claims description 9
230000001965 increasing effect Effects 0.000 claims description 9
239000000539 dimer Substances 0.000 claims description 8
238000006243 chemical reaction Methods 0.000 claims description 7
241000124008 Mammalia Species 0.000 claims description 5
150000004649 carbonic acid derivatives Chemical class 0.000 claims description 5
229940112141 dry powder inhaler Drugs 0.000 claims description 5
125000000524 functional group Chemical group 0.000 claims description 5
230000002163 immunogen Effects 0.000 claims description 5
239000007788 liquid Substances 0.000 claims description 5
239000007921 spray Substances 0.000 claims description 4
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
230000036765 blood level Effects 0.000 claims description 3
229920001515 polyalkylene glycol Polymers 0.000 claims description 3
239000013638 trimer Substances 0.000 claims description 3
150000001408 amides Chemical group 0.000 claims description 2
230000009870 specific binding Effects 0.000 claims description 2
238000013268 sustained release Methods 0.000 claims description 2
239000012730 sustained-release form Substances 0.000 claims description 2
125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 3
HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 claims 3
125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical group CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 1
229940071648 metered dose inhaler Drugs 0.000 claims 1
WDWDWGRYHDPSDS-UHFFFAOYSA-N methanimine Chemical group N=C WDWDWGRYHDPSDS-UHFFFAOYSA-N 0.000 claims 1
230000003285 pharmacodynamic effect Effects 0.000 abstract description 9
230000001976 improved effect Effects 0.000 abstract description 3
108700002854 polyethylene glycol(B1)- insulin Proteins 0.000 description 246
241001465754 Metazoa Species 0.000 description 72
238000009472 formulation Methods 0.000 description 71
239000000843 powder Substances 0.000 description 71
239000008103 glucose Substances 0.000 description 67
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 66
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 66
239000000243 solution Substances 0.000 description 38
229920000642 polymer Polymers 0.000 description 33
239000002552 dosage form Substances 0.000 description 32
241000700159 Rattus Species 0.000 description 27
239000002245 particle Substances 0.000 description 26
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
235000001014 amino acid Nutrition 0.000 description 24
150000001413 amino acids Chemical class 0.000 description 24
229940024606 amino acid Drugs 0.000 description 23
230000000694 effects Effects 0.000 description 20
230000015572 biosynthetic process Effects 0.000 description 18
239000003814 drug Substances 0.000 description 17
239000000945 filler Substances 0.000 description 17
238000003786 synthesis reaction Methods 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 16
239000004026 insulin derivative Substances 0.000 description 16
101000976075 Homo sapiens Insulin Proteins 0.000 description 15
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
238000002347 injection Methods 0.000 description 14
239000007924 injection Substances 0.000 description 14
108090000765 processed proteins & peptides Proteins 0.000 description 14
238000001990 intravenous administration Methods 0.000 description 13
230000006320 pegylation Effects 0.000 description 13
206010012601 diabetes mellitus Diseases 0.000 description 11
230000009885 systemic effect Effects 0.000 description 11
239000006185 dispersion Substances 0.000 description 10
229940079593 drug Drugs 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
102000004196 processed proteins & peptides Human genes 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
239000000047 product Substances 0.000 description 9
150000003839 salts Chemical class 0.000 description 9
238000001694 spray drying Methods 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
230000009471 action Effects 0.000 description 8
125000004429 atom Chemical group 0.000 description 8
239000000306 component Substances 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
239000008055 phosphate buffer solution Substances 0.000 description 8
238000006722 reduction reaction Methods 0.000 description 8
239000000523 sample Substances 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
239000000654 additive Substances 0.000 description 7
125000000217 alkyl group Chemical group 0.000 description 7
230000000975 bioactive effect Effects 0.000 description 7
230000021615 conjugation Effects 0.000 description 7
230000007515 enzymatic degradation Effects 0.000 description 7
230000007062 hydrolysis Effects 0.000 description 7
238000006460 hydrolysis reaction Methods 0.000 description 7
238000003780 insertion Methods 0.000 description 7
230000037431 insertion Effects 0.000 description 7
239000000126 substance Substances 0.000 description 7
BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 6
208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
239000004472 Lysine Substances 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
230000007423 decrease Effects 0.000 description 6
238000009826 distribution Methods 0.000 description 6
238000001035 drying Methods 0.000 description 6
229920001427 mPEG Polymers 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
239000000463 material Substances 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
238000003127 radioimmunoassay Methods 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
239000011550 stock solution Substances 0.000 description 6
235000000346 sugar Nutrition 0.000 description 6
150000008163 sugars Chemical class 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000008367 deionised water Substances 0.000 description 5
229910021641 deionized water Inorganic materials 0.000 description 5
230000003111 delayed effect Effects 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
230000009467 reduction Effects 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
241000894007 species Species 0.000 description 5
239000000725 suspension Substances 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
108010092217 Long-Acting Insulin Proteins 0.000 description 4
102000016261 Long-Acting Insulin Human genes 0.000 description 4
229940100066 Long-acting insulin Drugs 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
150000001241 acetals Chemical class 0.000 description 4
238000007792 addition Methods 0.000 description 4
235000012538 ammonium bicarbonate Nutrition 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000002051 biphasic effect Effects 0.000 description 4
238000007385 chemical modification Methods 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
150000004665 fatty acids Chemical group 0.000 description 4
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 4
238000002156 mixing Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000035772 mutation Effects 0.000 description 4
229920005615 natural polymer Polymers 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
230000004962 physiological condition Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
238000004007 reversed phase HPLC Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
238000003860 storage Methods 0.000 description 4
238000010254 subcutaneous injection Methods 0.000 description 4
239000007929 subcutaneous injection Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
238000012360 testing method Methods 0.000 description 4
125000003396 thiol group Chemical group [H]S* 0.000 description 4
PBKONEOXTCPAFI-UHFFFAOYSA-N 1,2,4-trichlorobenzene Chemical compound ClC1=CC=C(Cl)C(Cl)=C1 PBKONEOXTCPAFI-UHFFFAOYSA-N 0.000 description 3
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
108090000317 Chymotrypsin Proteins 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
102000008100 Human Serum Albumin Human genes 0.000 description 3
108091006905 Human Serum Albumin Proteins 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
150000001299 aldehydes Chemical class 0.000 description 3
239000001099 ammonium carbonate Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
229960002376 chymotrypsin Drugs 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000003480 eluent Substances 0.000 description 3
239000012634 fragment Substances 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
239000007789 gas Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
150000002430 hydrocarbons Chemical group 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000002502 liposome Substances 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
239000002808 molecular sieve Substances 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
230000007017 scission Effects 0.000 description 3
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
229960002317 succinimide Drugs 0.000 description 3
239000003643 water by type Substances 0.000 description 3
ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 2
AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 2
ASUGWWOMVNVWAW-UHFFFAOYSA-N 1-(2-methoxyethyl)pyrrole-2,5-dione Chemical compound COCCN1C(=O)C=CC1=O ASUGWWOMVNVWAW-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000629400 Homo sapiens Mesoderm-specific transcript homolog protein Proteins 0.000 description 2
101710186630 Insulin-1 Proteins 0.000 description 2
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
102000005237 Isophane Insulin Human genes 0.000 description 2
108010081368 Isophane Insulin Proteins 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
102100026821 Mesoderm-specific transcript homolog protein Human genes 0.000 description 2
102000015731 Peptide Hormones Human genes 0.000 description 2
108010038988 Peptide Hormones Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
238000000889 atomisation Methods 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
230000008021 deposition Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
150000002118 epoxides Chemical class 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
238000005189 flocculation Methods 0.000 description 2
230000016615 flocculation Effects 0.000 description 2
230000009477 glass transition Effects 0.000 description 2
230000010030 glucose lowering effect Effects 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
108010033606 insulin dimers Proteins 0.000 description 2
229960002725 isoflurane Drugs 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
239000003607 modifier Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000035515 penetration Effects 0.000 description 2
239000000813 peptide hormone Substances 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
150000008105 phosphatidylcholines Chemical class 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
229920001308 poly(aminoacid) Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000002953 preparative HPLC Methods 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000013049 sediment Substances 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
238000007873 sieving Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
150000005846 sugar alcohols Chemical class 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
229920003169 water-soluble polymer Polymers 0.000 description 2
239000000811 xylitol Substances 0.000 description 2
235000010447 xylitol Nutrition 0.000 description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
229960002675 xylitol Drugs 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
MLKLDGSYMHFAOC-AREMUKBSSA-N 1,2-dicapryl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC MLKLDGSYMHFAOC-AREMUKBSSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
125000005917 3-methylpentyl group Chemical group 0.000 description 1
QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
239000004604 Blowing Agent Substances 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
241001631457 Cannula Species 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
101001012217 Conus geographus Con-Ins G3 Proteins 0.000 description 1
101001012221 Conus tulipa Con-Ins T3 Proteins 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
241001269524 Dura Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
108010007979 Glycocholic Acid Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
101150034459 Parpbp gene Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
241000009328 Perro Species 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
241001415846 Procellariidae Species 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
229940123452 Rapid-acting insulin Drugs 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010026951 Short-Acting Insulin Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000950638 Symphysodon discus Species 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
108010036928 Thiorphan Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
206010066901 Treatment failure Diseases 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
NYRAVIYBIHCEGB-UHFFFAOYSA-N [K].[Ca] Chemical compound [K].[Ca] NYRAVIYBIHCEGB-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000007605 air drying Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
210000002821 alveolar epithelial cell Anatomy 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001412 amines Chemical group 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000002216 antistatic agent Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
IYRWEQXVUNLMAY-UHFFFAOYSA-N carbonyl fluoride Chemical compound FC(F)=O IYRWEQXVUNLMAY-UHFFFAOYSA-N 0.000 description 1
150000003857 carboxamides Chemical group 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000011208 chromatographic data Methods 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000005352 clarification Methods 0.000 description 1
235000020057 cognac Nutrition 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000012864 cross contamination Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000006240 deamidation Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000032798 delamination Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008355 dextrose injection Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000004821 distillation Methods 0.000 description 1
YNEZHFVWHPMBGA-UHFFFAOYSA-N ditert-butyl 2-(3-butoxycarbonyloxypropyl)propanedioate Chemical group CCCCOC(=O)OCCCC(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C YNEZHFVWHPMBGA-UHFFFAOYSA-N 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
230000000667 effect on insulin Effects 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000008393 encapsulating agent Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229950000206 estolate Drugs 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000013265 extended release Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229960001731 gluceptate Drugs 0.000 description 1
KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000004030 hiv protease inhibitor Substances 0.000 description 1
101150028517 hlb gene Proteins 0.000 description 1
229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
LFKYBJLFJOOKAE-UHFFFAOYSA-N imidazol-2-ylidenemethanone Chemical compound O=C=C1N=CC=N1 LFKYBJLFJOOKAE-UHFFFAOYSA-N 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
230000006362 insulin response pathway Effects 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
230000002608 insulinlike Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical class NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
HOQADATXFBOEGG-UHFFFAOYSA-N isofenphos Chemical compound CCOP(=S)(NC(C)C)OC1=CC=CC=C1C(=O)OC(C)C HOQADATXFBOEGG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
238000010902 jet-milling Methods 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000000832 lactitol Substances 0.000 description 1
235000010448 lactitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
229960003451 lactitol Drugs 0.000 description 1
JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
229940099584 lactobionate Drugs 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
235000014666 liquid concentrate Nutrition 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000012731 long-acting form Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000845 maltitol Substances 0.000 description 1
235000010449 maltitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
229940035436 maltitol Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229940127554 medical product Drugs 0.000 description 1
QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
231100000989 no adverse effect Toxicity 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000005457 optimization Methods 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000002905 orthoesters Chemical class 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000002559 palpation Methods 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000005426 pharmaceutical component Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
229940067605 phosphatidylethanolamines Drugs 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000765 poly(2-oxazolines) Polymers 0.000 description 1
229920000233 poly(alkylene oxides) Polymers 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000001294 propane Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000001012 protector Effects 0.000 description 1
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000007789 sealing Methods 0.000 description 1
125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000004513 sizing Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
229910001488 sodium perchlorate Inorganic materials 0.000 description 1
IBUIVNCCBFLEJL-UHFFFAOYSA-M sodium;phosphoric acid;chloride Chemical compound [Na+].[Cl-].OP(O)(O)=O IBUIVNCCBFLEJL-UHFFFAOYSA-M 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
LJJKNPQAGWVLDQ-SNVBAGLBSA-N thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229940073585 tromethamine hydrochloride Drugs 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
150000003673 urethanes Chemical class 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000002792 vascular Effects 0.000 description 1
229940070384 ventolin Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

LT2003107A 2001-05-21 2003-12-17 Chemiškai modifikuoto insulino įvedimas į plaučius LT5153B (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29242301P	2001-05-21	2001-05-21

Publications (2)

Publication Number	Publication Date
LT2003107A LT2003107A (en)	2004-05-25
LT5153B true LT5153B (lt)	2004-08-25

Family

ID=23124608

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT2003107A LT5153B (lt)	2001-05-21	2003-12-17	Chemiškai modifikuoto insulino įvedimas į plaučius

Country Status (35)

Country	Link
US (3)	US6838076B2 (fr)
EP (1)	EP1395294A4 (fr)
JP (1)	JP2004535401A (fr)
KR (1)	KR20030097876A (fr)
CN (2)	CN1314445C (fr)
AP (1)	AP1763A (fr)
AR (1)	AR033903A1 (fr)
AU (1)	AU2002303869B2 (fr)
BG (1)	BG108494A (fr)
BR (1)	BR0209896A (fr)
CA (1)	CA2447236A1 (fr)
CO (1)	CO5540371A2 (fr)
CZ (1)	CZ20033182A3 (fr)
EA (1)	EA007408B1 (fr)
EC (1)	ECSP034855A (fr)
GE (1)	GEP20063917B (fr)
HR (1)	HRP20030949A2 (fr)
HU (1)	HUP0400442A2 (fr)
IL (2)	IL158862A0 (fr)
IS (1)	IS7043A (fr)
LT (1)	LT5153B (fr)
LV (1)	LV13197B (fr)
MA (1)	MA26185A1 (fr)
MX (1)	MXPA03010649A (fr)
MY (1)	MY137181A (fr)
NO (1)	NO20035157D0 (fr)
NZ (1)	NZ529572A (fr)
OA (1)	OA13136A (fr)
PL (1)	PL366911A1 (fr)
SK (1)	SK15532003A3 (fr)
TN (1)	TNSN03116A1 (fr)
TR (1)	TR200400295T2 (fr)
WO (1)	WO2002094200A2 (fr)
YU (1)	YU98503A (fr)
ZA (1)	ZA200309085B (fr)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20060171899A1 (en) *	1998-12-10	2006-08-03	Akwete Adjei	Water-stabilized aerosol formulation system and method of making
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
BR0209896A (pt) *	2001-05-21	2004-08-17	Nektar Therapeutics	Composição de insulina para administração pulmonar, e, métodos para suprir insulina a um indivìduo mamìfero, para prover uma composição de insulina não-imunogênica e uma composição de insulina de efeito prolongado para administração ao pulmão de um indivìduo
EP1270012A1 (fr) *	2001-06-21	2003-01-02	Pfizer Products Inc.	Utilisation d'insuline administrée par voie pulmonaire pour le traitement du diabète
CA2470520A1 (fr) *	2001-12-21	2003-07-24	3M Innovative Properties Company	Compositions aerosols pharmaceutiques comportant un excipient au polyethylene-glycol fonctionnalise
ES2425392T3 (es)	2002-03-20	2013-10-15	Mannkind Corporation	Cartucho para un aparato de inhalación
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
ES2348230T3 (es)	2002-06-07	2010-12-01	Dyax Corp.	Prevención y reducción de la isquemia.
DK1596887T3 (da)	2003-02-26	2022-06-20	Nektar Therapeutics	Polymer-Faktor VIII-konjugat
EP1613272B1 (fr) *	2003-04-11	2013-12-18	Antriabio, Inc.	Procede de preparation de conjugues de proteines specifiques de site
EP1491554A1 (fr) *	2003-06-23	2004-12-29	CONARIS research institute AG	Solubles gp130-dimeres modifiée avec du PEG pour utilisation comme medicament
US20070020252A1 (en) *	2003-08-29	2007-01-25	Ladner Robert C	Modified protease inhibitors
US20050089515A1 (en)	2003-08-29	2005-04-28	Dyax Corp.	Poly-pegylated protease inhibitors
GB0328629D0 (en) *	2003-12-10	2004-01-14	Medpharm Ltd	Metered dose inhalation preparations
WO2005115477A2 (fr)	2004-04-13	2005-12-08	Quintessence Biosciences, Inc.	Conjugues de ribonuclease non naturelle utilises en tant qu'agents cytotoxiques
US7872095B2 (en)	2004-07-19	2011-01-18	Biocon Limited	Insulin-oligomer conjugates, formulations and uses thereof
ES2385934T3 (es)	2004-08-20	2012-08-03	Mannkind Corporation	Catálisis de la síntesis de dicetopiperazina.
HUE025151T2 (en)	2004-08-23	2016-01-28	Mannkind Corp	Diceto-piperazine salts for drug delivery
US20060046852A1 (en) *	2004-08-26	2006-03-02	Rowe Richard E	Wide area gaming system
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8245758B2 (en) *	2006-10-30	2012-08-21	GM Global Technology Operations LLC	Coulomb damped disc brake rotor and method of manufacturing
US20080206342A1 (en) *	2005-01-10	2008-08-28	Rosemary Kovelesky	Compositions and Methods For Increasing the Bioavailability of Pulmonarily Administered Insulin
EP1843790A2 (fr) *	2005-01-27	2007-10-17	Novo Nordisk A/S	Derives d'insuline conjugues avec des polymeres ramifies structurellement bien definis
TWI376234B (en) *	2005-02-01	2012-11-11	Msd Oss Bv	Conjugates of a polypeptide and an oligosaccharide
EP1846447B1 (fr)	2005-02-02	2013-08-21	Novo Nordisk A/S	Derives d'insuline
ES2428510T3 (es)	2005-02-02	2013-11-08	Novo Nordisk A/S	Derivados de insulina
EP1863840A1 (fr) *	2005-03-18	2007-12-12	Novo Nordisk A/S	Insuline monocatenaire pegylee
US20060271011A1 (en) *	2005-05-25	2006-11-30	Mock Bradley D	Methods and apparatus for indicating when a disposable component of a drug delivery system needs to be replaced
US7799344B2 (en)	2005-09-14	2010-09-21	Mannkind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US8168592B2 (en) *	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
US20070136092A1 (en) *	2005-11-30	2007-06-14	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US7974856B2 (en)	2005-11-30	2011-07-05	The Invention Science Fund I, Llc	Computational systems and methods related to nutraceuticals
US8000981B2 (en)	2005-11-30	2011-08-16	The Invention Science Fund I, Llc	Methods and systems related to receiving nutraceutical associated information
US20070289258A1 (en) *	2006-06-14	2007-12-20	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Individualized pharmaceutical selection and packaging
US20080033763A1 (en) *	2005-11-30	2008-02-07	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Methods and systems related to receiving nutraceutical associated information
US20070124218A1 (en) *	2005-11-30	2007-05-31	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational and/or control systems related to individualized nutraceutical selection and packaging
US20110145009A1 (en) *	2005-11-30	2011-06-16	Jung Edward K Y	Methods and systems related to transmission of nutraceutical associatd information
US20080103746A1 (en) *	2005-11-30	2008-05-01	Searete Llc, A Limited Liability Corporation	Systems and methods for pathogen detection and response
US20070124176A1 (en) *	2005-11-30	2007-05-31	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US10296720B2 (en) *	2005-11-30	2019-05-21	Gearbox Llc	Computational systems and methods related to nutraceuticals
US7827042B2 (en) *	2005-11-30	2010-11-02	The Invention Science Fund I, Inc	Methods and systems related to transmission of nutraceutical associated information
US20080114577A1 (en) *	2005-11-30	2008-05-15	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational methods and systems associated with nutraceutical related assays
US8340944B2 (en) *	2005-11-30	2012-12-25	The Invention Science Fund I, Llc	Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7927787B2 (en) *	2006-06-28	2011-04-19	The Invention Science Fund I, Llc	Methods and systems for analysis of nutraceutical associated components
US20080052114A1 (en) *	2005-11-30	2008-02-28	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational systems and methods related to nutraceuticals
US20080004905A1 (en) *	2006-06-28	2008-01-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Methods and systems for analysis of nutraceutical associated components
US20070174128A1 (en) *	2005-11-30	2007-07-26	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US8297028B2 (en)	2006-06-14	2012-10-30	The Invention Science Fund I, Llc	Individualized pharmaceutical selection and packaging
BRPI0620819A2 (pt) *	2005-12-30	2011-11-22	Zensun Shangai Science & Technology Ltd	uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero
US8039431B2 (en)	2006-02-22	2011-10-18	Mannkind Corporation	Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US20070292404A1 (en) *	2006-03-27	2007-12-20	Biosynexus Incorporated	Antimicrobial polymer conjugates
WO2007149594A2 (fr)	2006-06-23	2007-12-27	Quintessence Biosciences, Inc.	Ribonucléases modifiées
PL1873166T3 (pl)	2006-06-30	2011-03-31	Conaris Res Institute Ag	Ulepszone dimery sgp 130Fc
US8298801B2 (en) *	2006-07-17	2012-10-30	Quintessence Biosciences, Inc.	Methods and compositions for the treatment of cancer
WO2008015099A2 (fr) *	2006-07-31	2008-02-07	Novo Nordisk A/S	Insulines pegylées à extensions
AU2007281998B2 (en) *	2006-08-04	2014-02-20	Pharmathene Inc.	Long half-life recombinant butyrylcholinesterase
JP5864834B2 (ja)	2006-09-22	2016-02-17	ノボ・ノルデイスク・エー／エス	プロテアーゼ耐性のインスリンアナログ
US8110655B2 (en)	2006-11-13	2012-02-07	Auxagen, Inc.	Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor
WO2008084051A1 (fr) *	2007-01-12	2008-07-17	Novo Nordisk A/S	Mélanges d'insuline pégylée et d'insuline à action rapide pour une administration pulmonaire
EP2134181A4 (fr) *	2007-02-28	2011-09-28	Serina Therapeutics Inc	Polyoxazolines activées et composition comprenant celles-ci
US20140011964A1 (en)	2007-02-28	2014-01-09	Serina Therapeutics, Inc.	Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
ES2563038T3 (es)	2007-04-30	2016-03-10	Novo Nordisk A/S	Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
WO2009020434A1 (fr) *	2007-08-07	2009-02-12	Nanomaterials Technology Pte Ltd	Procédé de fabrication de particules de protéine microdimensionnée
US8946201B2 (en) *	2007-08-27	2015-02-03	Saint Louis University	Methods for inhibiting TGF-β
CA2702043A1 (fr) *	2007-10-08	2009-04-16	Quintessence Biosciences, Inc.	Compositions et procedes pour des therapies a base de ribonuclease
CN101939023B (zh)	2007-10-16	2016-08-03	百康有限公司	可经口给药的固体药物组合物及其方法
CN101795680A (zh) *	2007-11-16	2010-08-04	波苏蛋白试剂公司	稳定蛋白质的辅剂
CN101970477B (zh)	2008-03-14	2014-12-31	诺沃-诺迪斯克有限公司	蛋白酶稳定的胰岛素类似物
JP5749155B2 (ja)	2008-03-18	2015-07-15	ノボ・ノルデイスク・エー／エス	プロテアーゼ安定化アシル化インスリンアナログ
DK2293833T3 (en)	2008-06-13	2016-05-23	Mannkind Corp	DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
TWI451876B (zh) *	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
US8488661B2 (en) *	2008-06-13	2013-07-16	Verizon Patent And Licensing Inc.	Systems and methods for data streaming
JP5479465B2 (ja)	2008-06-20	2014-04-23	マンカインドコーポレイション	吸入努力をリアルタイムにプロファイルする対話式機器および方法
TWI494123B (zh)	2008-08-11	2015-08-01	Mannkind Corp	超快起作用胰島素之用途
CN102159219B (zh) *	2008-09-16	2015-06-24	圣路易斯大学	提高转化生长因子-β信号发送的方法
US20110171312A1 (en) *	2008-09-19	2011-07-14	Nektar Therapeutics	Modified therapeutic peptides, methods of their preparation and use
US8680263B2 (en)	2008-09-19	2014-03-25	Nektar Therapeutics	Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010039985A1 (fr)	2008-10-01	2010-04-08	Quintessence Biosciences, Inc.	Ribonucléases thérapeutiques
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
CA2748490C (fr)	2008-12-29	2016-10-04	Mannkind Corporation	Analogues substitues de dicetopiperazine pour une utilisation en tant qu'agents d'administration de medicaments
US8637454B2 (en)	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
CA2754595C (fr)	2009-03-11	2017-06-27	Mannkind Corporation	Appareil, systeme et procede de mesure de resistance d'un inhalateur
US8551528B2 (en)	2009-06-12	2013-10-08	Mannkind Corporation	Diketopiperazine microparticles with defined specific surface areas
PE20120918A1 (es)	2009-07-31	2012-08-14	Sanofi Aventis Deutschland	Profarmacos que comprenden un conjugado de insulina-conector
UA108475C2 (uk) *	2009-07-31	2015-05-12	Санофі-Авентіс Дойчланд Гмбх	Композиція інсуліну тривалої дії
EP2488172A4 (fr)	2009-10-13	2014-08-13	Univ Michigan	Compositions de dendrimères et procédés de synthèse
US9016147B2 (en)	2009-11-03	2015-04-28	Mannkind Corporation	Apparatus and method for simulating inhalation efforts
AU2010340358B2 (en)	2009-12-21	2014-07-24	Pharmathene, Inc.	Recombinant butyrylcholinesterases and truncates thereof
RS62853B1 (sr)	2010-01-06	2022-02-28	Takeda Pharmaceuticals Co	Proteini koji vezuju kalikrein plazme
US9981017B2 (en)	2010-04-02	2018-05-29	Hanmi Science Co., Ltd.	Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) *	2010-04-02	2012-06-06	Hanmi Holdings Co Ltd	Conjugado de insulina donde se usa un fragmento de inmunoglobulina
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
EP2438930A1 (fr)	2010-09-17	2012-04-11	Sanofi-Aventis Deutschland GmbH	Promédicaments comprenant un conjugué de liaison d'exendine
CN103635489B (zh)	2011-01-06	2016-04-13	戴埃克斯有限公司	血浆前激肽释放酶结合蛋白
JP2014509603A (ja)	2011-03-15	2014-04-21	ノヴォノルディスクアー／エス	システイン置換を含むヒトインスリン類似体およびヒトインスリン誘導体
CN102675452B (zh) *	2011-03-17	2015-09-16	重庆富进生物医药有限公司	具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
MY180552A (en)	2011-04-01	2020-12-02	Mannkind Corp	Blister package for pharmaceutical cartridges
WO2012174472A1 (fr)	2011-06-17	2012-12-20	Mannkind Corporation	Microparticules de dicétopipérazine de capacité élevée
EP2776053A1 (fr)	2011-10-24	2014-09-17	MannKind Corporation	Procédés et compositions pour traiter la douleur
CN102504022A (zh) *	2011-11-30	2012-06-20	苏州元基生物技术有限公司	含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
BR112014025132A2 (pt)	2012-04-11	2017-07-11	Novo Nordisk As	formulações de insulina
US9457096B2 (en)	2012-07-06	2016-10-04	Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet)	Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
SG11201500218VA (en)	2012-07-12	2015-03-30	Mannkind Corp	Dry powder drug delivery systems and methods
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
EP2925345B1 (fr)	2012-12-03	2018-09-05	Merck Sharp & Dohme Corp.	Méthode de préparation d'insuline et d'analogues d'insuline à base du peptide de la partie terminale carboxy (ctp) o-glycosylé
AU2014228415B2 (en)	2013-03-15	2018-08-09	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
MX394255B (es)	2013-07-18	2025-03-24	Mannkind Corp	Composiciones farmaceuticas en polvo seco estables al calor y metodos
EP3030294B1 (fr)	2013-08-05	2020-10-07	MannKind Corporation	Appareil d'insufflation
KR102302634B1 (ko)	2013-09-13	2021-09-14	더 스크립스 리서치 인스티튜트	변형된 치료제 및 이의 조성물
ES2676065T3 (es)	2013-10-07	2018-07-16	Novo Nordisk A/S	Nuevo derivado de un análogo de la insulina
EP3082797A4 (fr)	2013-12-18	2017-12-13	The California Institute for Biomedical Research	Agents thérapeutiques modifiés, conjugués lipide-peptide agrafés, et compositions les comprenant
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
CA2969301A1 (fr)	2014-12-01	2016-06-09	Ferring B.V.	Administration d'un inhibiteur de signalisation detrans-signalisation par il-6 selectif
WO2016089206A2 (fr)	2014-12-01	2016-06-09	Ferring B.V.	Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
CN108602893A (zh)	2015-12-11	2018-09-28	戴埃克斯有限公司	血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
EP3442998A4 (fr)	2016-04-12	2020-04-01	Cell And Molecular Tissue Engineering, LLC	Systèmes, procédés et produits permettant de réduire au minimum les réactions tissulaires et les lésions tissulaires au niveau d'un site de perfusion
CN109952116B (zh) *	2016-11-02	2021-02-09	陶氏环球技术有限责任公司	固体非水性凝胶空气增香剂
HUE060149T2 (hu)	2016-12-16	2023-02-28	Novo Nordisk As	Inzulint tartalmazó gyógyászati készítmények
JP2023510854A (ja)	2020-01-13	2023-03-15	武田薬品工業株式会社	小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用
JP2024522196A (ja)	2021-06-09	2024-06-11	ザスクリプスリサーチインスティテュート	長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4652548A (en)	1981-08-27	1987-03-24	Eli Lilly And Company	Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
US4654324A (en)	1981-08-27	1987-03-31	Eli Lilly And Company	Human proinsulin pharmaceutical formulations
DOP1982004086A (es)	1981-08-27	1988-03-22	Lilly Co Eli	Formula farmaceutica que comprende insulina humana y proinsulina humana
US4839341A (en)	1984-05-29	1989-06-13	Eli Lilly And Company	Stabilized insulin formulations
EP0400472B1 (fr)	1989-05-27	1996-04-03	Sumitomo Pharmaceuticals Company, Limited	Procédé pour la préparation de dérivés de polyéthylène glycol et protéine modifiée.
US5342940A (en)	1989-05-27	1994-08-30	Sumitomo Pharmaceuticals Company, Limited	Polyethylene glycol derivatives, process for preparing the same
US5652214A (en) *	1989-06-05	1997-07-29	Cephalon, Inc.	Treating disorders by application of insulin-like growth factors and analogs
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
JP3051145B2 (ja)	1990-08-28	2000-06-12	住友製薬株式会社	新規なポリエチレングリコール誘導体修飾ペプチド
US6565841B1 (en) *	1991-03-15	2003-05-20	Amgen, Inc.	Pulmonary administration of granulocyte colony stimulating factor
US6024090A (en) *	1993-01-29	2000-02-15	Aradigm Corporation	Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5681811A (en)	1993-05-10	1997-10-28	Protein Delivery, Inc.	Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en)	1993-05-10	1994-10-25	Protein Delivery, Inc.	Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5565215A (en)	1993-07-23	1996-10-15	Massachusettes Institute Of Technology	Biodegradable injectable particles for imaging
EP0761683B1 (fr)	1994-05-20	2005-02-02	Hisamitsu Pharmaceutical Co., Inc.	Proteine ou polypeptide, procede et intermediaires permettant leur preparation
US5730990A (en)	1994-06-24	1998-03-24	Enzon, Inc.	Non-antigenic amine derived polymers and polymer conjugates
US5874064A (en) *	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
DE19628143A1 (de)	1996-07-12	1998-01-15	Basf Ag	Verfahren zur Herstellung einer wäßrigen Polymerisatdispersion
DE69800640T2 (de)	1997-01-29	2001-07-05	Polymasc Pharmaceuticals Plc, London	Pegylationsverfahren
PT1025125E (pt)	1997-10-24	2003-11-28	Novo Nordisk As	Derivativos agregados da insulina humana
US5985263A (en)	1997-12-19	1999-11-16	Enzon, Inc.	Substantially pure histidine-linked protein polymer conjugates
ES2242412T3 (es)	1998-07-27	2005-11-01	Emisphere Technologies, Inc.	Compuestos que permiten administrar agentes activos y composiciones a base de estos compuestos.
WO2000033866A1 (fr) *	1998-12-04	2000-06-15	Provalis Uk Limited	Composition pharmaceutique contenant de l'insuline
US6627228B1 (en)	1999-01-08	2003-09-30	Emisphere Technologies, Inc.	Polymeric delivery agents and delivery agents compounds
US6309633B1 (en)	1999-06-19	2001-10-30	Nobex Corporation	Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US7169889B1 (en) *	1999-06-19	2007-01-30	Biocon Limited	Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6323311B1 (en) *	1999-09-22	2001-11-27	University Of Utah Research Foundation	Synthesis of insulin derivatives
WO2001068141A2 (fr)	2000-03-17	2001-09-20	Maxygen Aps	Dispersions de conjugues polypeptidiques
CA2445494A1 (fr) *	2001-05-11	2002-11-21	Aradigm Corporation	Optimisation des proprietes moleculaires et formulation de proteines delivrees par inhalation
BR0209896A (pt) *	2001-05-21	2004-08-17	Nektar Therapeutics	Composição de insulina para administração pulmonar, e, métodos para suprir insulina a um indivìduo mamìfero, para prover uma composição de insulina não-imunogênica e uma composição de insulina de efeito prolongado para administração ao pulmão de um indivìduo
US6828297B2 (en)	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
DE60226613D1 (de) *	2001-08-16	2008-06-26	Baxter Int	Darreichungsformen welche mikropartikel und treibgas enthalten

2002
- 2002-05-21 BR BR0209896-2A patent/BR0209896A/pt not_active Application Discontinuation
- 2002-05-21 US US10/154,057 patent/US6838076B2/en not_active Expired - Lifetime
- 2002-05-21 IL IL15886202A patent/IL158862A0/xx unknown
- 2002-05-21 SK SK1553-2003A patent/SK15532003A3/sk not_active Application Discontinuation
- 2002-05-21 JP JP2002590921A patent/JP2004535401A/ja active Pending
- 2002-05-21 WO PCT/US2002/016464 patent/WO2002094200A2/fr not_active Ceased
- 2002-05-21 YU YU98503A patent/YU98503A/sh unknown
- 2002-05-21 CZ CZ20033182A patent/CZ20033182A3/cs unknown
- 2002-05-21 HR HR20030949A patent/HRP20030949A2/xx not_active Application Discontinuation
- 2002-05-21 HU HU0400442A patent/HUP0400442A2/hu unknown
- 2002-05-21 EP EP02731931A patent/EP1395294A4/fr not_active Withdrawn
- 2002-05-21 CA CA002447236A patent/CA2447236A1/fr not_active Abandoned
- 2002-05-21 AP APAP/P/2003/002918A patent/AP1763A/en active
- 2002-05-21 GE GE5398A patent/GEP20063917B/en unknown
- 2002-05-21 KR KR10-2003-7014954A patent/KR20030097876A/ko not_active Ceased
- 2002-05-21 AR ARP020101877A patent/AR033903A1/es not_active Application Discontinuation
- 2002-05-21 CN CNB028103556A patent/CN1314445C/zh not_active Expired - Fee Related
- 2002-05-21 TR TR2004/00295T patent/TR200400295T2/xx unknown
- 2002-05-21 AU AU2002303869A patent/AU2002303869B2/en not_active Ceased
- 2002-05-21 OA OA1200300305A patent/OA13136A/en unknown
- 2002-05-21 MY MYPI20021867A patent/MY137181A/en unknown
- 2002-05-21 PL PL02366911A patent/PL366911A1/xx not_active Application Discontinuation
- 2002-05-21 CN CNA2007100855527A patent/CN101045166A/zh active Pending
- 2002-05-21 NZ NZ529572A patent/NZ529572A/en unknown
- 2002-05-21 EA EA200301222A patent/EA007408B1/ru not_active IP Right Cessation
- 2002-05-21 MX MXPA03010649A patent/MXPA03010649A/es active IP Right Grant
2003
- 2003-04-01 US US10/405,190 patent/US6890518B2/en not_active Expired - Fee Related
- 2003-07-08 TN TNPCT/US2002/016464A patent/TNSN03116A1/en unknown
- 2003-11-13 IL IL158862A patent/IL158862A/en not_active IP Right Cessation
- 2003-11-19 IS IS7043A patent/IS7043A/is unknown
- 2003-11-20 CO CO03102566A patent/CO5540371A2/es unknown
- 2003-11-20 NO NO20035157A patent/NO20035157D0/no unknown
- 2003-11-20 EC EC2003004855A patent/ECSP034855A/es unknown
- 2003-11-21 LV LVP-03-131A patent/LV13197B/en unknown
- 2003-11-21 MA MA27413A patent/MA26185A1/fr unknown
- 2003-12-17 LT LT2003107A patent/LT5153B/lt not_active IP Right Cessation
- 2003-12-22 BG BG108494A patent/BG108494A/xx unknown
2004
- 2004-11-02 US US10/980,652 patent/US20050152848A1/en not_active Abandoned
- 2004-11-21 ZA ZA200309085A patent/ZA200309085B/en unknown

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRANGE J. ET AL.: "Chemical stability of insulin. 1. Hydrolytic degradation during storage of pharmaceutical preparations", PHARM RES., 1992, pages 715 - 726, XP009034399, DOI: doi:10.1023/A:1015835017916
EDWARDS DA ET AL.: "Large porous particles for pulmonary drug delivery", SCIENCE, 1997, pages 1868 - 1871, XP000857276, DOI: doi:10.1126/science.276.5320.1868
HOFFMAN A., ZIV E.: "Pharmacokinetic considerations of new insulin formulations and routes of administration", CLIN PHARMACOKINET., 1997, pages 285 - 301
JOHN S. PATTON, JULIE BUKAR, SUDHA NAGARAJAN: "Inhaled insulin", ADV DRUG DELIV REV., 1999, pages 235 - 247
LIU F. ET AL.: "Glucose-Induced Release of Glycosylpoly(ethylene glycol) Insulin Bound to a Soluble Conjugate of Concanavalin A", BIOCONJUGATE CHEM., 1997, pages 664 - 672, XP002972016, DOI: doi:10.1021/bc970128e
ROBBINS DC ET AL.: "Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients.", DIABETES, 1987, pages 838 - 841
UCHIO T. ET AL.: "Site-specific insulin conjugates with enhanced stability and extended action profile.", ADV DRUG DELIV REV., 1999, pages 289 - 306, XP002363507, DOI: doi:10.1016/S0169-409X(98)00078-7

Also Published As

Publication number	Publication date
US6838076B2 (en)	2005-01-04
EA200301222A1 (ru)	2004-08-26
NZ529572A (en)	2006-02-24
AP2003002918A0 (en)	2003-12-31
EP1395294A4 (fr)	2006-01-11
IL158862A (en)	2008-07-08
LT2003107A (en)	2004-05-25
SK15532003A3 (sk)	2004-06-08
BG108494A (en)	2004-07-30
CO5540371A2 (es)	2005-07-29
MY137181A (en)	2009-01-30
JP2004535401A (ja)	2004-11-25
NO20035157D0 (no)	2003-11-20
OA13136A (en)	2006-12-13
YU98503A (sh)	2006-05-25
AU2002303869B2 (en)	2007-08-16
KR20030097876A (ko)	2003-12-31
EP1395294A2 (fr)	2004-03-10
TNSN03116A1 (en)	2005-12-23
LV13197B (en)	2004-10-20
EA007408B1 (ru)	2006-10-27
US20030118510A1 (en)	2003-06-26
HRP20030949A2 (en)	2005-04-30
WO2002094200A3 (fr)	2003-02-20
ZA200309085B (en)	2004-11-22
TR200400295T2 (tr)	2005-04-21
HUP0400442A2 (hu)	2005-03-29
US20030216542A1 (en)	2003-11-20
US6890518B2 (en)	2005-05-10
CN101045166A (zh)	2007-10-03
PL366911A1 (en)	2005-02-07
CN1582171A (zh)	2005-02-16
IL158862A0 (en)	2004-05-12
ECSP034855A (es)	2004-03-23
MXPA03010649A (es)	2005-10-05
IS7043A (is)	2003-11-19
MA26185A1 (fr)	2004-07-01
BR0209896A (pt)	2004-08-17
CN1314445C (zh)	2007-05-09
GEP20063917B (en)	2006-09-11
WO2002094200A2 (fr)	2002-11-28
AP1763A (en)	2007-08-02
CA2447236A1 (fr)	2002-11-28
CZ20033182A3 (cs)	2004-09-15
US20050152848A1 (en)	2005-07-14
AR033903A1 (es)	2004-01-07

Publication	Publication Date	Title
LT5153B (lt)	2004-08-25	Chemiškai modifikuoto insulino įvedimas į plaučius
AU2002303869A1 (en)	2003-05-08	Pulmonary administration of chemically modified insulin
US11167035B2 (en)	2021-11-09	Insulin compositions and method of making a composition
JP5721432B2 (ja)	2015-05-20	アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
JP5550338B2 (ja)	2014-07-16	ペグ化持続型インスリン
US20110171312A1 (en)	2011-07-14	Modified therapeutic peptides, methods of their preparation and use
EP2262539B1 (fr)	2015-07-15	Conjugués insuline-albumine
US8987197B2 (en)	2015-03-24	Protease stabilized, pegylated insulin analogues and uses thereof
EP2364735A2 (fr)	2011-09-14	Conjugé de GLP-1 et de PEG ramafié
EP2017288A1 (fr)	2009-01-21	Analogues de l'insuline pégylés, stabilisés à la protéase

Legal Events

Date	Code	Title	Description
2010-12-27	MM9A	Lapsed patents	Effective date: 20100521